Videos

Founding Partner of Curatio Scientia speaks on her upcoming panel at Trade & Channel Strategies 2023. 

Trade & Channel Strategies 2023: An Interview with Cheryl Allen of Curatio Scientia

Articles

AstraZeneca's deal to acquire Icosavax is expected to bolster AstraZeneca’s Vaccines & Immune Therapies late-stage pipeline with IVX-A12, a potential first-in-class vaccine for both respiratory syncytial virus and human metapneumovirus.

AstraZeneca Announces Acquisition of Respiratory Vaccine Developer

Bristol Myers Squibb strikes deal with SystImmune for the rights to codevelop and sell a potentially first-in-class EGFRxHER3 bispecific antibody-drug conjugate that has shown promise in non-small cell lung cancer and breast cancer.

Bristol Myers Squibb, SystImmune Announce Deal to Codevelop, Commercialize Bispecific Antibody-Drug Conjugate  

Phase III INTerpath-002 trial will evaluate the novel individualized neoantigen therapy V940 (mRNA-4157) with Keytruda (pembrolizumab) as an adjuvant treatment for patients with non-small cell lung cancer.

Merck and Moderna Announce Phase III Trial of Combination Therapy for Non-Small Cell Lung Cancer

Adults and children aged 1 year and older are eligible for the IV formulation of 
Cresemba for invasive aspergillosis and invasive mucormycotic, whereas the prescribed capsule is only indicated for adults and children 6 years of age and older.

Cresemba Granted Expanded Indication by FDA for Pediatric Patients With Invasive Aspergillosis, Invasive Mucormycosis

The rise in demand represents the third consecutive month of year-on-year growth. 

October Air Freight Numbers Indicate a Continued Increase in Demand, Says IATA

FDA approves bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy for the treatment of sickle cell disease, which affects approximately 100,000 people in the United States.

Lyfgenia, Casgevy Become First Cell-Based Gene Therapies to Gain FDA Approval for Sickle Cell Disease

Study analyzes and predicts how conditions in research and development can be predicted via computer simulation.

A Guide on Determining Stability of Molecular Crystals in Pharmaceutical Drug Development

PrEPVacc tested two different combinations of vaccines to determine whether either can prevent HIV infection in populations at risk of acquiring the virus.

Limited Evidence of Efficacy Halts Study of Novel HIV Vaccine, Oral PrEP

An independent Data Monitoring Committee found that Keytruda in combination with chemotherapy followed by Keytruda plus Lynparza did not produce an improved overall survival benefit vs. Keytruda in combination with chemotherapy followed by Keytruda plus a placebo in patients with metastatic squamous non-small cell lung cancer.

News